comparemela.com

Latest Breaking News On - Robyn karnauskas - Page 9 : comparemela.com

Pfizer s 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. PFE, lowering the price target to $36 from $42. While PFE provided…

Robyn karnauskasSeagen incPfizer incTruist securitiesReaking news

Pfizer s 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast - Seagen (NASDAQ:SGEN), Pfizer (NYSE:PFE)

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE), 

Robyn karnauskasSeagen incPfizer inc

Curis s stock rises as analysts see the next Pharmacyclics

Shares of Curis Inc. CRIS, gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with…

Robyn karnauskasCuris incTruist securitiesReaking news

Curis shares rise as analysts see the next Pharmacyclics

Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target

United statesRobyn karnauskasAbbvie incCuris incAmerican society of hematologyTruist securitiesAmerican societyArticle normalBiotechnology servicesCancer drugsHealthcare life sciencesSpecialized drugs medicationsAnalysts amp 39 comments recommendationsOwnership changesAcquisitions mergers shareholdingsAcquisitions mergers

Why Coherus BioSciences Was Plummeting This Week

The company has been punished harshly for a worse-than-expected quarter.

Coherus biosciencesJason mccarthyRobyn karnauskasMaxim groupJason kolbertTruist securitie robyn karnauskas

vimarsana © 2020. All Rights Reserved.